Methylprednisolone reduces liver damage signs in cholestasis infantsÂ
Two weeks of oral methylprednisolone twice a day as an add-therapy significantly lowered signs of liver damage and inflammation among infants with cholestasis, a…
Steve Bryson, PhD, Science Writer—
Articles by Steve Bryson
Blood test augurs liver survival after Kasai procedure in biliary atresia
A blood-based biomarker of body-wide inflammation called a low systemic immune-inflammation index (SII) before a standard Kasai surgical procedure can accurately predict post-surgery liver…
PBC treatment setanaxib eases signs of liver damage: Trial data
Six months of Calliditas Therapeutics‘ investigational therapy setanaxib safely and significantly reduced signs of liver damage in people with hard-to-treat primary biliary cholangitis…
Dosing begins in Phase 2 trial of DD01 in treating fatty liver disease
Dosing has begun in a Phase 2 clinical trial evaluating the safety and efficacy of DD01 in people with one of two forms of fatty…
CDA Foundation grants aim to help US hepatitis patients find doctors
In its efforts to connect diagnosed but untreated hepatitis B or C patients with physicians, the Center for Disease Analysis (CDA) Foundation has…
Biliary atresia children show delays after living donor liver transplant
Children with biliary atresia show developmental problems, including language delays, following a living donor liver transplant (LDLT) in infancy and a second surgery to…
Baby with rare PFIC type thrives after liver transplant: Case study
A living donor liver transplant successfully managed liver failure in a 6-month-old boy with progressive familial intrahepatic cholestasis type 8 (PFIC8) that was unresponsive to…
Clinical genome sequencing aids in rare genetic disease diagnosis: Study
Clinical genome sequencing, or cGS, testing to detect a rare genetic disease such as Alagille syndrome, resulted in a positive diagnosis of varying disorders…
HCV, HIV opt-out testing program to now be evaluated nationwide
A team of researchers, backed by a grant totaling more than $3 million, will study the feasibility of a nationwide opt-out testing program to detect…
FDA breakthrough designation granted to larsucosterol for AH
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to larsucosterol, Durect’s investigational therapy for people with severe alcohol-associated hepatitis…